Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease

Nature

Volumn 519, Issue 7544, 2015, Pages 472-476

  Lee, Dong I ^a   Zhu, Guangshuo ^a   Sasaki, Takashi ^b   Cho, Gun Sik ^a   Hamdani, Nazha ^c   Holewinski, Ronald ^a,d   Jo, Su Hyun ^e   Danner, Thomas ^a   Zhang, Manling ^a   Rainer, Peter P ^a   Bedja, Djahida ^a   Kirk, Jonathan A ^a   Ranek, Mark J ^a   Dostmann, Wolfgang R ^f   Kwon, Chulan ^a   Margulies, Kenneth B ^g   Van Eyk, Jennifer E ^a,d   Paulus, Walter J ^c   Takimoto, Eiki ^a   Kass, David A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e Kangwon National University   (South Korea)

^f UNIVERSITY OF VERMONT   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIC GMP; FIBRONECTIN; GELATINASE A; MYOSIN HEAVY CHAIN BETA; NEUROHORMONE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PF 04447943; PF 04449613; PF 9613; PHOSPHODIESTERASE; PHOSPHODIESTERASE 9A; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL; SMALL INTERFERING RNA; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; UNCLASSIFIED DRUG; CYCLIC AMP PHOSPHODIESTERASE; NATRIURETIC FACTOR; PDE9A PROTEIN, HUMAN; PDE9A PROTEIN, MOUSE;

CARDIOVASCULAR DISEASE; ENZYME ACTIVITY; INHIBITION; MAMMAL; MOLECULAR ANALYSIS; NITRIC OXIDE; PATHOLOGY; PEPTIDE; SIGNALING;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE ACTIVATION; GENE SILENCING; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART VENTRICLE OVERLOAD; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION INITIATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA VALVE STENOSIS; C57BL MOUSE; CARDIAC MUSCLE; CARDIOMEGALY; COMPLICATION; DEFICIENCY; DRUG EFFECTS; ENZYMOLOGY; GENETICS; METABOLISM; MUSCLE CELL; PHYSIOLOGICAL STRESS; PRESSURE; SIGNAL TRANSDUCTION;

MAMMALIA;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ANIMALS; AORTIC VALVE STENOSIS; CARDIOMEGALY; CYCLIC GMP; HUMANS; MALE; MICE; MICE, INBRED C57BL; MUSCLE CELLS; MYOCARDIUM; NATRIURETIC PEPTIDES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE INHIBITORS; PRESSURE; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; UP-REGULATION;

EID: 84925728806     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature14332     Document Type: Article

References (30)

1. Takimoto, E., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nature Med. 11, 214-222 (2005).
2. Kukreja, R. C., Salloum, F. N., Das, A. Cyclic guanosine monophosphate signaling and phosphodiesterase-5 inhibitors in cardioprotection. J. Am. Coll. Cardiol. 59, 1921-1927 (2012).
3. Mullershausen, F., Russwurm, M., Koesling, D., Friebe, A. In vivo reconstitution of the negative feedback in nitric oxide/cGMP signaling: role of phosphodiesterase type 5 phosphorylation. Mol. Biol. Cell 15, 4023-4030 (2004).
4. Castro, L. R., Verde, I., Cooper, D. M., Fischmeister, R. Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 113, 2221-2228 (2006).
5. Takimoto, E., et al. Compartmentalization of cardiac b-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation 115, 2159-2167 (2007).
6. Carnicer, R., Crabtree, M. J., Sivakumaran, V., Casadei, B., Kass, D. A. Nitric oxide synthases in heart failure. Antioxid. Redox Signal. 18, 1078-1099 (2013).
7. Soderling, S. H., Bayuga, S. J., Beavo, J. A. Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J. Biol. Chem. 273, 15553-15558 (1998).
8. Fisher, D. A., Smith, J. F., Pillar, J. S., St Denis, S. H., Cheng, J. B. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem. 273, 15559-15564 (1998).
9. Conti, M., Beavo, J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 76, 481-511 (2007).
10. Kleiman, R. J., et al. Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo. J. Pharmacol. Exp. Ther. 341, 396-409 (2012).
11. Heckman, P. R., Wouters, C., Prickaerts, J. Phosphodiesterase inhibitors as a target for cognitionenhancement in aging and Alzheimer's disease: a translational overview. Curr. Pharm. Des. 21, 317-331 (2015).
12. Sharma, K., Kass, D. A. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ. Res. 115, 79-96 (2014).
13. Nausch, L. W., Ledoux, J., Bonev, A. D., Nelson, M. T., Dostmann, W. R. Differential patterning of cGMPin vascularsmoothmuscle cells revealed by single GFP-linked biosensors. Proc. Natl Acad. Sci. USA 105, 365-370 (2008).
14. Singh, G., Kuc, R. E., Maguire, J. J., Fidock, M., Davenport, A. P. Novel snake venom ligand dendroaspis natriuretic peptide is selective for natriuretic peptide receptor-A in human heart: downregulation of natriuretic peptide receptor-A in heart failure. Circ. Res. 99, 183-190 (2006).
15. Davis, J., Burr, A. R., Davis, G. F., Birnbaumer, L., Molkentin, J. D. A. TRPC6-dependent pathway for myofibroblast transdifferentiation and wound healing in vivo. Dev. Cell 23, 705-715 (2012).
16. Koitabashi, N., et al. Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyteNFAT activation: novel mechanism of cardiac stress modulation by PDE5 inhibition. J. Mol. Cell. Cardiol. 48, 713-724 (2010).
17. Kinoshita, H., et al. Inhibition of TRPC6 channel activity contributes to the antihypertrophic effects of natriuretic peptides-guanylyl cyclase-A signaling in the heart. Circ. Res. 106, 1849-1860 (2010).
18. Stangherlin, A., et al. cGMP signals modulate cAMP levels in a compartmentspecific manner to regulate catecholamine-dependent signaling in cardiac myocytes. Circ. Res. 108, 929-939 (2011).
19. Pilz, R. B., Broderick, K. E. Role of cyclicGMP in gene regulation. Front. Biosci. 10, 1239-1268 (2005).
20. Oka, T., et al. Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability. Circ. Res. 98, 837-845 (2006).
21. Maurice, D. H., et al. Advances in targeting cyclic nucleotide phosphodiesterases. Nature Rev. Drug Discov. 13, 290-314 (2014).
22. Greene, S. J., et al. The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J. Am Heart Assoc. 2, e000536 (2013).
23. Redfield, M. M., et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. J. Am. Med. Assoc. 309, 1268-1277 (2013).
24. van Heerebeek, L., et al. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 126, 830-839 (2012).
25. McMurray, J. J., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 993-1004 (2014).
26. Zakeri, R., Burnett, J. C. Designer natriuretic peptides: a vision for the future of heart failure therapeutics. Can. J. Physiol. Pharmacol. 89, 593-601 (2011).
27. Seo, K., et al. Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy. Proc.Natl Acad. Sci. USA 111, 1551-1556 (2014).
28. Verhoest, P. R., et al. Designanddiscovery of 6-[(3S, 4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyr an-4-yl)-1, 5-dihydro-4Hpyrazolo[ 3, 4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders. J. Med. Chem. 55, 9045-9054 (2012).
29. Zhou, B., et al. Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature 454, 109-113 (2008).
30. Kirk, J. A., et al. Cardiac resynchronization sensitizes the sarcomere to calciumby reactivating GSK-3beta. J. Clin. Invest. 124, 129-139 (2014).